key: cord-0720925-ojr558x6 authors: Desai, Hardik D.; Sharma, Kamal; Shah, Anchal; Patoliya, Jaimini; Patil, Anant; Hooshanginezhad, Zahra; Grabbe, Stephan; Goldust, Mohamad title: Can SARS‐CoV‐2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review date: 2021-10-31 journal: J Cosmet Dermatol DOI: 10.1111/jocd.14521 sha: 23b133eda6cbdd9be2f049b3cdfce606592bcc94 doc_id: 720925 cord_uid: ojr558x6 INTRODUCTION: Although the COVID‐19 vaccination is deemed safe, exact incidence and nature if adverse effects, particularly dermatological ones, are still unknown. OBJECTIVE: To describe the demographic, clinical, morphological characteristics, outcomes, and timing of development of herpes zoster to the various COVID‐19 vaccines. And to identify on whether COVID‐19 vaccine has temporal relationship between development of herpes zoster (HZ). METHODS: We have performed a systemic review of articles from PubMed and Embase using MeSH and keywords like “Shingles,” “Herpes zoster,” “Varicella zoster,” “COVID‐19,” “Vaccine,” “SARS‐CoV‐2.” No filters including country of publication, language, type of articles were applied. Individual case report references were filtered for any pertinent cases. RESULTS: A total of 54 cases consisting of 27 male and 27 female patients have been reported. There were cases with known risk factors for herpes zoster, which included age more than 50 years (n = 36), immunological disorders (n = 10), chronic disease (n = 25), metabolic disorder (n = 13), malignancy (n = 4), and psychiatric disorder (n = 2). The mean (SD) period between development of herpes zoster and COVID‐19 vaccination was 7.64 (6.92) days. Majority of the cases were from the high‐income and/or middle‐income countries. 86.27% of the cases of HZ were reported due to mRNA vaccine. Thirty‐six patients 36/45 (80%) developed herpes zoster following the priming dose of COVID‐19 vaccine among those who received mRNA vaccine. CONCLUSION: We could not establish definite link but there may be possible association between COVID‐19 vaccine and shingles. Large‐scale studies may help to understand the cause‐effect relationship. The World Health Organization (WHO) announced the coronavirus disease 2019 (COVID-19) outbreak a pandemic on March 11, 2020 and the development of a safe and effective COVID-19 vaccine quickly became a worldwide priority. As of July 2021, 27.6% of the world population has received at least one dose of COVID-19 vaccine. 1 In an attempt to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral transmission, non-replicating viral vector vaccines, DNA-based or RNA-based vaccines, and inactivated vaccines, protein subunit recombinant vaccines have been developed recently. Adverse events after vaccination (AEAV) might be a coincidence or a direct result of the vaccine. In order to answer this question, a temporal relationship between vaccination and AEAV is required, as well as a biological mechanism is necessary to explain the link. The platform for COVID-19 vaccine leaders is based on gene therapy. Still, it is the matter of research for the dermatologists, to investigate the long-term consequences of older generation vaccines. As a result, the long-term consequences of vaccinations based on gene therapy remain essentially unknown. COVID -19 vaccines have been reported to be associated with reactogenicity with symptoms such as fever, fatigue, and headache being frequently reported. This is due to the vaccines' intrinsic character, even though they have been shown to be safe in clinical trials. 2, 3 Although the COVID-19 vaccination is deemed safe, adverse effects, particularly dermatological ones, are still unknown. Clinical studies have reported that the most common cutaneous adverse effects are injection site reaction and pruritus; allergic reactions such as urticaria and widespread erythematous rash. 4 In the literature, various cutaneous conditions have been observed including anecdotal cases of erythema multiforme with morbilliform rash, delayed-type hypersensitivity reaction, bullous drug eruption, pernio/chilblains (eg, "COVID toes"), erythromelalgia, and pityriasisrosea-like exanthems, and herpes zoster (HZ). [5] [6] [7] [8] Studies have reported development of herpes zoster due to SARS-CoV-2 infection either at the time of disease progression or following recovery from the disease. In the context of COVID-19 pandemic, studies observed that COVID-19 is associated lymphopenia, particularly CD3+, CD8+ lymphocytes, and functional impairment of CD4+ 2 | ME THOD A systemic review was conducted due to the sparse but quickly increasing scientific literature on HZ and COVID-19. We performed a search in PubMed and Embase using "Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)" guidelines by using MeSH and keywords like "Shingles," "Herpes zoster," "Varicella zoster," "COVID-19," "Vaccine," "SARS-CoV-2." Boolean operators ("OR"; "AND") were used to combine the search results. No filters including country of publication, language, type of articles were applied. Individual case report references were filtered for any pertinent cases. The findings were saved in an EndNote library. The search strategy is shown in PRISMA diagram ( Figure 1 ). Articles published until August 14, 2021 were included. We selected all the available individual case reports and case series. During phase 1, two authors (H.D. and K.S.) independently assessed the abstracts, titles, and categories of research that met the requirements. The disagreements were resolved by consensus with another two authors (J.P and M.G). Based on the inclusion criteria, the second phase of the search involved assessing full-text articles in order to identify items for data extraction. Data from the article were curated and summarized in the form of age, gender, country of origin, symptoms and clinical characteristic of the lesion, vaccine type, and dose, days until symptom onset of post-vaccination, location of the lesion, past medical history/comorbidities, medical intervention during hospitalization and confirmatory test. Descriptive analysis and data collection were performed using Microsoft Excel software. The search yielded a total of 121 and 67 hits from Embase and PubMed, respectively. We identified 14 articles that met as per the study requirement. The search yielded a total of 54 patients consisting of 27 male and 27 females. Cases were reported worldwide including USA, 10, 11 Lebanon, 12 Turkey, [13] [14] [15] Greece, 16 Italy, 17 India, 18 Israel, 19 Finland, 20 Taiwan, 21 Spain, 22 and Portugal. 23 There were cases with known risk factors for herpes zoster, which included age more than 50 years (n = 36), immunological disorders (n = 10), chronic disease (n = 25), metabolic disorder (n = 13), malignancy (n = 4), and psychiatric disorder (n = 2). Table 1 shows the details of cases. The mean (SD) period between herpes zoster and COVID-19 vaccination was 7.64 (6.92) days ( Figure 2 ). In most of the cases, 52 Majority of the herpes zoster cases diagnosed clinically (40/54), followed by VZV PCR (11/54), VZV IgG (1/54), 10 and skin biopsy (2/54). 17, 18 Various dermatomal lesion has been observed including trunk, 10 hips/buttocks or inguinal region, 19 herpes zoster ophthalmicus (HZO), 10, 19 upper limb, 10 thigh, 12 and abdomen and flank. 10 There were 3 cases who developed lymphadenopathy including cervical and inguinal lymphadenopathy. 19, 22 Postherpetic neuralgia was reported in 3 cases. 16 Prior VZV infection was reported in 13 cases, 10,19,20 and 5 cases 10, 11, 19 reported prior zoster vaccination. Vaccinations have been found to have a high level of reactogenicity, with headache, fever, and tiredness being more prevalent than with other vaccines. The distinctive inflammatory nature of these vaccinations may explain the higher-than-usual reported adverse effects. These vaccinations have been proven to strengthen the cellular immune system and generate a Th1-type response with high IFNg, TNFa, and IL2 levels. As a result, they may hypothetically play a role in the flare-up of dermatological disorders including psoriasis, lichen planus, vitiligo, and other diseases with a known Th1 function in pathogenesis. 24 Herpes zoster following vaccination is rarely reported in the literature. Studies have reported herpes zoster following vaccination of inactivated vaccines for influenza, hepatitis A, and rabies and Japanese encephalitis, and yellow fever. In this review, we studied baseline clinical and demographic characteristics, and timing of development of herpes zoster following COVID-19 vaccine. HZ has been reported due to almost all types of COVID-19 vaccine. Among, majority of the cases were reported due to mRNA vaccine. However, underreporting, fluctuating data quality, the absence of stimulation of innate immunity might be the connection between COVID-19 vaccine and HZ development. 15 The stimulation of these receptors has been related to the reactivation of VZV, allowing the latent virus to remain dormant in the afflicted people. 14 The COVID-19 immunization may lead to the production of type I IFNs and other inflammatory cytokines, activating T-and B-cell immunity and negatively affecting antigen expression, resulting in herpes zoster reactivation. [16] [17] [18] The peak of antigen expression is determined by the administration method and vaccine composition, which is another approach to modulate the immune response. [11] [12] [13] Furthermore, herpes zoster is more common in HIV patients with lower CD4 cell counts, underlining the significance of T-cell immunity in sustaining VZV latency. 26, 27 According to Sahin U et al., 28 it is said to be "consistent with" a causal association. As per WHO updated guidelines on causality definitions, a "probable" association suggests a temporal relationship and the existence of a biologic mechanism for causal association between the vaccination and the occurrence. 25, 30, 31 Of 54 herpes zoster reported cases, 52 (96.29%) of the patients developed it at the defined higher risk timeframe (1-21 days after the initial dose). 23 As a result, the AEAV may be categorized as "compatible with," and a "likely" causal relationship based on the World Health Organization Working Group can be presented, indicating the existence of a temporal link and a credible physiological mechanism. 25,30-32 Despite the fact that the case fatality rate (CFR) for HZ is exceedingly low in COVID-19 patients. 9 Herpes zoster is often associated with disability, especially among aged individuals, and available management only decreases viral shedding reducing the risk of transmission and prevents post-herpetic neuralgia and the severity and the duration of pain. In immunocompetent people over the age of 50, the recombinant zoster vaccination is indicated. 33 reactivation of VZV following COVID-19 immunization and its effects on cellular immunity with regard to its role in etiology, prognosis, and manifestation. 22 Our study was limited by publication bias, small sample size, missing data, and lack of generalizability in demographics of the series analyzed. In the majority of the cases, diagnosis of HZ was pertinent to the HZ clinical findings. Our study does not establish any causality or definite link but draws the attention to a possible association between COVID-19 vaccine and shingles. Large-scale immunological, epidemiological, and clinical studies may help to understand the cause-effect relationship. Based on the criteria of temporal connection with vaccination and a plausible biological link, HZ appears to be a "possible" but uncommon AEAV. Furthermore, these findings may be therapeutically relevant in deciding whether to use antiviral as a temporary prophylactic prior to immunization for individuals who are at a greater risk of VZV reactivation following SARS-CoV-2 vaccination. Open access funding enabled and organized by Projekt DEAL. None. We confirm that the manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met and that each author believes that the manuscript represents honest work. This study was conducted using published online material, hence the ethical approval is waived. The data that support the findings of this study are available from the corresponding author upon reasonable request. Hardik D. Desai https://orcid.org/0000-0001-5373-8146 Anant Patil https://orcid.org/0000-0002-9455-4025 Mohamad Goldust https://orcid.org/0000-0002-8646-1179 Available at https://ourwo rldin data.org/covid -vacci nations Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases Delayed localized hypersensitivity reactions to the moderna COVID-19 vaccine: a case series Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine Can COVID-19 increase the risk of herpes zoster? A narrative review 20 Post-COVID-19 vaccinerelated shingles cases seen at the Las Vegas Dermatology clinic and sent to us via social media Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination Herpes zoster emergence following mRNA COVID-19 vaccine Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect? Reactivation of Varicella zoster virus after vaccination for SARS-CoV-2 Small vessel vasculitis related to varicella-zoster virus after Pfizer-BioNTech COVID-19 vaccine Herpes zoster after inactivated COVID-19 vaccine: a cutaneous adverse effect of the vaccine Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine Herpes zoster following COVID-19 vaccine: report of 3 cases Varicellazoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases Herpes zoster following SARS-CoV-2 vaccination -a series of four cases Implication of mass COVID-19 vaccination on dermatology practice in 2021 Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) Herpes zoster, immunological deterioration and disease progression in HIV-1 infection High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors BNT162b2 induces SARS-CoV-2 neutralizing antibodies and T cells in humans Safety and immunogenicity of SARS-CoV-2 mRNA-1273, vaccine in older individuals Causality Working Group of the Clinical Immunization Safety Assessment network. Algorithm to assess causality after individual adverse events following immunizations Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use COVID-19 Vaccine Safety Update Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines Public Health Service (PHS), Centers for Disease Control (CDC)/Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS). 1990-3/26/2021. CDC WONDER On-line Database Coronavirus Vaccine-Weekly Summary of Yellow Card Reporting COVID-19 Vaccine AstraZeneca Analysis Print. Available on COVID-19 mRNA Pfizer-BioNTech Vaccine Analysis Print How to cite this article CoV-2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review